Journal
FRONTIERS IN ONCOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2023.1124730
Keywords
bullous pemphigoid; PD-1; fruquintinib; sintilimab; pMMR; MSS mCRC
Categories
Ask authors/readers for more resources
Immunotherapy is effective in treating many cancers but can cause immune-related adverse effects, such as bullous pemphigoid. This article reports a case of bullous pemphigoid caused by PD-1 in a colorectal cancer patient. The patient showed no significant adverse effects after tapering methylprednisone and achieved partial remission for over 8 months.
Immunotherapy has become a very effective treatment for many cancers. It has a unique set of immune system-related adverse effects, collectively known as immune-related adverse events (irAEs). Skin toxicities are the most common irAEs, of which bullous pemphigoid, although rare, is potentially life-threatening and affects patients' survival. In this article, we report the treatment of bullous pemphigoid caused by programmed cell death protein-1 (PD-1) in a case of proficient mismatch repair (pMMR)/microsatellite stable (MSS) colorectal cancer. No significant adverse effects were observed in the patient after methylprednisone was tapered to 4 mg twice a day. No new skin lesions occurred recently in the patient and the original skin lesions healed. In particular, the patient's immunotherapy was not stopped and the best outcome was a partial remission of the disease, lasting for more than 8 months.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available